Tüdőrák: vizsgálatok itt: Japán

In Japán 136 Also abroad 2733

136 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Akashi, Chuo Ku, Hidaka, Hirakata-shi, Kanazawa, Kashihara-shi, Kashiwa-shi, Koto-Ku, Kyoto, Matsuyama, Nagaizumi-chō, Nagoya, Niigata, Osakasayama-Shi, Sagamihara, Sapporo, Sendai, Toyoake-shi, Wakayama, Yokohama
Életkor
18 év and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
1/2. fázisTaking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Chiba, Osaka, Tokyo, Wakayama
Életkor
18 év and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata, Okayama, Osaka, Sendai, Shizuoka, Tokyo, Wakayama
Életkor
18 év and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Akashi, Beppu-shi, Bunkyo-ku, Fukuoka, Kiyose, Kochi, Kure, Kurume, Kyoto, Nagaizumi-chō, Okayama, Ōmura, Osaka, Sakai, Sendai, Suita, Tsu
Életkor
18 év and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
3. fázisTaking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Bunkyo Ku, Fukuoka, Hamamatsu, Hidaka, Hirakata, Kobe, Nagoya, Nishinomiya, Okayama, Sagamihara, Sakai, Sendai, Yokohama
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
1/2. fázisTaking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
Életkor
18 év and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
3. fázisTaking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Asahikawa, Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kasama, Kashiwa, Kobe, Kōtō City, Kyoto, Matsuyama, Nagaizumi-cho,Sunto-gun, Nagasaki, Nagoya, Natori, Niigata, Okayama, Sakai, Sapporo, Ube, Utsunomiya, Wakayama, Yokohama, Yonago
Életkor
18 év and over
People
1264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
1. fázisTaking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Shizuoka, Tokyo
Életkor
18 év and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
3. fázisTaking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bunkyo-ku, Fukuoka, Himeji, Hirakata, Kashiwa, Kitaadachi, Kobe, Nagoya, Niigata, Osaka, Sagamihara, Sakai, Sapporo, Sendai, Ube, Yonago
Életkor
18 év and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
1. fázisTaking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
Életkor
18 év and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
1/2. fázisTaking people
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Where
Kashiwa, Osakasayama-Shi, Tsukiji
Életkor
18 év and over
People
675 worldwide
Run by
BlossomHill Therapeutics
See details and how to joinNCT06706076
3. fázisTaking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kobe, Kōtō City, Kyoto, Nagaizumi-cho,Sunto-gun, Nagoya, Natori, Niigata, Sakai, Sapporo, Wakayama, Yokohama, Yonago
Életkor
18 év and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
2. fázisTaking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Chuo Ku
Életkor
18 év and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
2. fázisTaking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Himeji, Matsusaka, Niigata, Shizuoka, Tokyo, Wakayama
Életkor
18 év and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
3. fázisTaking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Bunkyo, Fukuoka, Himeji, Hirakata, Hirosaki, Kashiwa, Kawasaki, Koto, Kumamoto, Kurume, Matsusaka, Matsuyama, Niigata, Osaka, Ōta, Ōta-ku, Sendai, Shimotsugagun, Shinjuku, Shiwa-gun, Suntogun, Takatsuki, Toyoake, Ube, Ureshino, Yokohama
Életkor
18 év and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
2. fázisTaking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Chūō, Kyoto, Nagoya, Sagamihara, Saitama, Sakai, Tokyo, Yokohama
Életkor
18 év and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
1. fázisTaking people
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Where
Kashiwa
Életkor
18 év and over
People
156 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07660055
2/3. fázisTaking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Ageo, Akashi, Aomori, Bunkyō City, Chūōku, Funabashi, Himeji, Hiroshima, Iizuka, Iwakuni, Kanagawa, Kanazawa, Kumamoto, Kurashiki, Kurume, Matsusaka, Matsuyama, Meguro City, Mibu, Morioka, Nagaizumi-chō, Nagasaki, Nagoya, Niigata, Nishinomiya, Osaka, Saitama, Sakai, Sapporo, Sendai, Shibukawa, Toyama, Wakayama, Yokohama
Életkor
18 év and over
People
1580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
1. fázisTaking people
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Where
Chūōku
Életkor
18 év and over
People
77 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07166601
3. fázisTaking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Akashi-shi, Bunkyo-ku, Bunkyo Ku, Chuo Ku, Hirakata-shi, Kashiwa, Kurume-shi, Nagoya, Natori-shi, Niigata, Sapporo, Toyoake
Életkor
18 év and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
3. fázisTaking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Aichi, Nagoya, Aichi, Toyoake, Chiba, Kashiwa, Fukuoka, Fukuoka, Fukuoka, Kitakyushu, Hiroshima, Hiroshima, Hokkaido, Sapporo, Kanagawa, Sagamihara, Kanagawa, Yokohama, Miyagi, Sendai, Niigata, Niigata, Okayama, Okayama, Osaka, Hirakata, Osaka, Osaka, Osaka, Sakai, Saitama, Hidaka, Saitama, Kitaadachi-gun, Shizuoka, Sunto-gun, Tochigi, Shimotsuke, Tokyo, Bunkyo-ku, Tokyo, Chuo-ku, Tokyo, Koto-ku, Tokyo, Shinjuku-ku, Wakayama, Wakayama
Életkor
18 év and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
3. fázisTaking people
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Where
Tokyo
Életkor
18 év and over
People
1200 worldwide
Run by
Takeda
See details and how to joinNCT07217301 · EU 2026-525659-94-00
2/3. fázisTaking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Akashi, Fukushima, Hidaka-shi, Iwakuni, Kanazawa, Kashihara, Nagasaki, Nagoya, Nankoku-shi, Nishinomiya-Shi, Osaka, Sagamihara, Sakai-Shi, Sendai, Toon-shi, Toyama
Életkor
18 év and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
3. fázisTaking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Bunkyo-ku, Chuo-ku, Fujieda-shi, Fukuoka, Fukushima, Fukuyama, Habikino-shi, Higashiibaraki-gun, Hirakata-shi, Hirosaki-shi, Hiroshima, Kasama-shi, Kashiwa-shi, Kitakyushu-shi, Kobe, Kumamoto, Kurashiki-shi, Kurume-shi, Meguro-ku, Miyazaki, Nagaoka-shi, Nagoya, Natori-shi, Osaka, Ota-shi, Sagamihara-shi, Sakai-shi, Sapporo, Sendai, Shinagawa-ku, Shinjuku-ku, Shiwa-gun, Takarazuka-shi, Toyama, Tsu, Ube-shi, Utsunomiya, Wakayama, Yamagata, Yokohama
Életkor
18 év and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
3. fázisTaking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Chiba, Fukuoka, Hirakata, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kitaadachi-gun, Kobe, Koto, Matsusaka, Nagoya, Nankoku, Niigata, Osaka, Ōta, Ōta-ku, Sendai, Shimotsuga-gun, Shinjuku, Takarazuka, Tōon, Toyoake, Ube, Ureshino, Yokohama
Életkor
18 év and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00